Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse

Neuroscience

Volumn 171, Issue 1, 2010, Pages 162-172

  Dawe, G S ^a   Nagarajah, R ^a   Albert, R ^b   Casey, D E ^c   Gross, K W ^d   Ratty, A K ^b,e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SCHOOL OF PHYSICS   (Malaysia)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e Chakra Biotech Pte Ltd   (Singapore)

Author keywords

Animal model; Antipsychotic; Chakragati mice; Drug screening; Hyperactivity; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; HISTAMINE H1 RECEPTOR; IMIPRAMINE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; ZIPRASIDONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CAGE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SCREENING; FEMALE; HYPERACTIVITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR OCCUPANCY; RECEPTOR UPREGULATION; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERKINESIS; INHIBITION (PSYCHOLOGY); MICE; MICE, INBRED C57BL; MICE, NEUROLOGIC MUTANTS; MICE, TRANSGENIC; MOTOR ACTIVITY; PROTEIN BINDING; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SCHIZOPHRENIA;

EID: 77957870433     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.08.061     Document Type: Article

References (47)

1. Assié M.B., Dominguez H., Consul-Denjean N., Newman-Tancredi A. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn Schmiedebergs Arch Pharmacol 2006, 373:441-450.
2. Baruch I., Hemsley D.R., Gray J.A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 1988, 176:598-606.
3. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 1990, 47:181-188.
4. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001, 156:234-258.
5. Buckley P.F. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 2007, 68(Suppl 6):5-9.
6. Chen J., Lipska B.K., Weinberger D.R. Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. Biol Psychiatry 2006, 59:1180-1188.
7. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192:481-483.
8. Creese I., Iversen S.D. The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Res 1975, 83:419-436.
9. Dawe G.S., Ratty A.K. The chakragati mouse: a mouse model for rapid in vivo screening of antipsychotic drug candidates. Biotechnol J 2007, 2:1344-1352.
10. Fitzgerald L.W., Miller K.J., Ratty A.K., Glick S.D., Teitler M., Gross K.W. Asymmetric elevation of striatal dopamine D2 receptors in the chakragati mouse: neurobehavioral dysfunction in a transgenic insertional mutant. Brain Res 1992, 580:18-26.
11. Fitzgerald L.W., Ratty A.K., Miller K.J., Ellsworth M.K., Glick S.D., Gross K.W. Ontogeny of hyperactivity and circling behavior in a transgenic insertional mutant mouse. Behav Neurosci 1991, 105:755-763.
12. Fitzgerald L.W., Ratty A.K., Teitler M., Gross K.W., Glick S.D. Specificity of behavioral and neurochemical dysfunction in the chakragati mouse: a novel genetic model of a movement disorder. Brain Res 1993, 608:247-258.
13. Geyer M.A. Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotox Res 2008, 14:71-78.
14. Geyer M., Moghaddam B. Animal models relevant to schizophrenia disorder. Neuropsychopharmacology: the fifth generation of progress 2002, Lippincott/Williams & Wilkins, Philadelphia, PA. K.L. Davis, C. Charney, J.T. Coyle, C. Nemeroff (Eds.).
15. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003, 305:625-631.
16. Koike H., Ibi D., Mizoguchi H., Nagai T., Nitta A., Takuma K., Nabeshima T., Yoneda Y., Yamada K. Behavioral abnormality and pharmacologic response in social isolation-reared mice. Behav Brain Res 2009, 202:114-121.
17. Kumari V., Sharma T. Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research. Psychopharmacology (Berl) 2002, 162:97-101.
18. Kumari V., Soni W., Sharma T. Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry 1999, 156:1046-1051.
19. Kumari V., Soni W., Sharma T. Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics. Schizophr Res 2002, 55:139-146.
20. Li Q., Cheung C., Wei R., Hui E.S., Feldon J., Meyer U., Chung S., Chua S.E., Sham P.C., Wu E.X., McAlonan G.M. Prenatal immune challenge is an environmental risk factor for brain and behavior change relevant to schizophrenia: evidence from MRI in a mouse model. PLoS One 2009, 4:e6354.
21. Lipska B.K. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci 2004, 29:282-286.
22. Lodge D.J., Grace A.A. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res 2009, 204:306-312.
23. Maj J., Rogóz Z., Skuza G. Antidepressant drugs increase the locomotor hyperactivity induced by MK-801 in rats. J Neural Transm Gen Sect 1991, 85:169-179.
24. Maj J., Rogóz Z., Skuza G., Sowinska H. The effect of antidepressant drugs on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist. Neuropharmacology 1992, 31:685-691.
25. Maj J., Wedzony K. Repeated treatment with imipramine or amitriptyline increases the locomotor response of rats to (+)-amphetamine given into the nucleus accumbens. J Pharm Pharmacol 1985, 37:362-364.
26. Murray J.B. Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research. J Psychol 2002, 136:319-327.
27. Ögren S.O., Cott J.M., Hall H. Sedative/anxiolytic effects of antidepressants in animals. Acta Psychiatr Scand Suppl 1981, 290:277-288.
28. O'Tuathaigh C.M., Babovic D., O'Meara G., Clifford J.J., Croke D.T., Waddington J.L. Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour. Neurosci Biobehav Rev 2007, 31:60-78.
29. Peroutka S.J., Synder S.H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 1980, 137:1518-1522.
30. Pietropaolo S., Singer P., Feldon J., Yee B.K. The postweaning social isolation in C57BL/6 mice: preferential vulnerability in the male sex. Psychopharmacology (Berl) 2008, 197:613-628.
31. Powell S.B., Zhou X., Geyer M.A. Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res 2009, 204:282-294.
32. Ratty A.K., Fitzgerald L.W., Titeler M., Glick S.D., Mullins J.J., Gross K.W. Circling behavior exhibited by a transgenic insertional mutant. Brain Res Mol Brain Res 1990, 8:355-358.
33. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000, 68:29-39.
34. Sams-Dodd F., Lipska B.K., Weinberger D.R. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology (Berl) 1997, 132:303-310.
35. Seeman P. Glutamate and dopamine components in schizophrenia. J Psychiatry Neurosci 2009, 34:143-149.
36. Seeman P., Guan H.C. Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2(High) receptor. Synapse 2009, 63:935-939.
37. Seeman P., Guan H.C. Glutamate agonists for treating schizophrenia have affinity for dopamine D2High and D3 receptors. Synapse 2009, 63:705-709.
38. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261:717-719.
39. Seillier A., Giuffrida A. Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Behav Brain Res 2009, 204:410-415.
40. Sumiyoshi T., Suzuki K., Sakamoto H., Yamaguchi N., Mori H., Shiba K., Yokogawa K. Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy. Neuropsychopharmacology 1995, 12:57-64.
41. Torres G., Hallas B.H., Gross K.W., Spernyak J.A., Horowitz J.M. Magnetic resonance imaging and spectroscopy in a mouse model of schizophrenia. Brain Res Bull 2008, 75:556-561.
42. Torres G., Hallas B.H., Vernace V.A., Jones C., Gross K.W., Horowitz J.M. A neurobehavioral screening of the ckr mouse mutant: implications for an animal model of schizophrenia. Brain Res Bull 2004, 62:315-326.
43. Torres G., Meeder B.A., Hallas B.H., Gross K.W., Horowitz J.M. Preliminary evidence for reduced social interactions in Chakragati mutants modeling certain symptoms of schizophrenia. Brain Res 2005, 1046:180-186.
44. Torres G., Meeder B.A., Hallas B.H., Spernyak J.A., Mazurchuk R., Jones C., Gross K.W., Horowitz J.M. Ventricular size mapping in a transgenic model of schizophrenia. Brain Res Dev Brain Res 2005, 154:35-44.
45. Verma V., Tan C.H., Ong W.Y., Grigoryan G.A., Jones C.A., Stolzberg D., Salvi R., Gross K.W., Ratty A.K., Dawe G.S. The chakragati mouse shows deficits in prepulse inhibition of acoustic startle and latent inhibition. Neurosci Res 2008, 60:281-288.
46. Vohs J.L., Chambers R.A., Krishnan G.P., O'Donnell B.F., Hetrick W.P., Kaiser S.T., Berg S., Morzorati S.L. Auditory sensory gating in the neonatal ventral hippocampal lesion model of schizophrenia. Neuropsychobiology 2009, 60:12-22.
47. Zebrowska-Lupina I., Kozyrska C., Stelmasiak M. Interaction between antidepressants and alpha-adrenergic receptor blocking agents. Pol J Pharmacol Pharm 1980, 32:673-680.